Filtered By:
Infectious Disease: COVID-19

This page shows you your search results in order of relevance. This is page number 4.

Order by Relevance | Date

Total 157 results found since Jan 2013.

Development of Lipid Nanoparticles for the Delivery of Macromolecules Based on the Molecular Design of pH-Sensitive Cationic Lipids
Chem Pharm Bull (Tokyo). 2021;69(12):1141-1159. doi: 10.1248/cpb.c21-00705.ABSTRACTConsiderable efforts have been made on the development of lipid nanoparticles (LNPs) for delivering of nucleic acids in LNP-based medicines, including a first-ever short interfering RNA (siRNA) medicine, Onpattro, and the mRNA vaccines against the coronavirus disease 2019 (COVID-19), which have been approved and are currently in use worldwide. The successful rational design of ionizable cationic lipids was a major breakthrough that dramatically increased delivery efficiency in this field. The LNPs would be expected to be useful as a platform...
Source: Chemical and Pharmaceutical Bulletin - December 2, 2021 Category: Drugs & Pharmacology Authors: Yusuke Sato Source Type: research

Lipid nanoparticle formulations for optimal RNA-based topical delivery to murine airways
CONCLUSION: LNP formulations enable the delivery of RNA payloads into human airway epithelial cells, and in the murine respiratory system; they can be delivered to nasal mucosa and lower respiratory tract via intranasal delivery. The composition of helper lipids in LNPs crucially modulates transfection efficiencies in airway epithelia, highlighting their importance in effective delivery of therapeutic products for airways diseases.PMID:35688311 | DOI:10.1016/j.ejps.2022.106234
Source: Cancer Control - June 10, 2022 Category: Cancer & Oncology Authors: A Tam J Kulkarni K An L Li D R Dorscheid G K Singhera P Bernatchez Gsd Reid Kyt Chan D Witzigmann P R Cullis D D Sin C J Lim Source Type: research

Middle east respiratory syndrome corona virus spike glycoprotein suppresses macrophage responses via DPP4-mediated induction of IRAK-M and PPAR γ.
Middle east respiratory syndrome corona virus spike glycoprotein suppresses macrophage responses via DPP4-mediated induction of IRAK-M and PPARγ. Oncotarget. 2017 Jan 19;: Authors: Al-Qahtani AA, Lyroni K, Aznaourova M, Tseliou M, Al-Anazi MR, Al-Ahdal MN, Alkahtani S, Sourvinos G, Tsatsanis C Abstract Middle East Respiratory Syndrome Corona Virus (MERS-CoV) is transmitted via the respiratory tract and causes severe Acute Respiratory Distress Syndrome by infecting lung epithelial cells and macrophages. Macrophages can readily recognize the virus and eliminate it. MERS-CoV infects cells via its Spike (...
Source: Oncotarget - January 25, 2017 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model.
CONCLUSIONS: Our pangolin coronavirus GX_P2V is a workable model for 2019-nCoV research. CEP, selamectin and mefloquine hydrochloride are potential drugs for treating 2019-nCoV infection. Our results strongly suggest that CEP is a wide-spectrum inhibitor of pan-betacoronavirus, and clinical trial of CEP for treatment of 2019-nCoV infection is warranted. PMID: 32149769 [PubMed - as supplied by publisher]
Source: Chinese Medical Journal - March 5, 2020 Category: General Medicine Authors: Fan HH, Wang LQ, Liu WL, An XP, Liu ZD, He XQ, Song LH, Tong YG Tags: Chin Med J (Engl) Source Type: research

Optimizing use of theranostic nanoparticles as a life-saving strategy for treating COVID-19 patients
On the 30th of January 2020, the World Health Organization fired up the sirens against a fast spreading infectious disease caused by a newly discovered Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and gave this disease the name COVID-19. While there is currently no specific treatment for COVID-19, several off label drugs approved for other indications are being investigated in clinical trials across the globe.In the last decade, theranostic nanoparticles were reported as promising tool for efficiently and selectively deliver therapeutic moieties (i.e. drugs, vaccines, siRNA, peptide) to target sites of infe...
Source: Theranostics - July 3, 2020 Category: Molecular Biology Authors: Rasha Itani, Mansour Tobaiqy, Achraf Al Faraj Tags: Review Source Type: research

Viruses, Vol. 12, Pages 924: Viral Vectors Applied for RNAi-Based Antiviral Therapy
m RNA interference (RNAi) provides the means for alternative antiviral therapy. Delivery of RNAi in the form of short interfering RNA (siRNA), short hairpin RNA (shRNA) and micro-RNA (miRNA) have demonstrated efficacy in gene silencing for therapeutic applications against viral diseases. Bioinformatics has played an important role in the design of efficient RNAi sequences targeting various pathogenic viruses. However, stability and delivery of RNAi molecules have presented serious obstacles for reaching therapeutic efficacy. For this reason, RNA modifications and formulation of nanoparticles have proven useful for non-...
Source: Viruses - August 22, 2020 Category: Virology Authors: Kenneth Lundstrom Tags: Review Source Type: research